Rhenman & Partners Asset Management AB grew its holdings in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 66.1% during the third quarter, Holdings Channel.com reports. The firm owned 166,061 shares of the company’s stock after buying an additional 66,061 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Immunovant were worth $6,375,000 […]
Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for shares of Immunovant in a research note issued to investors on Tuesday, February 13th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $2.16 for the year, […]
Research analysts at Wolfe Research began coverage on shares of Immunovant (NASDAQ:IMVT – Get Free Report) in a research report issued to clients and investors on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $55.00 price target on the stock. Wolfe Research’s price objective would suggest a potential upside of 45.50% from […]
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Beats Estimates By $0 07 EPS kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Immunovant (NASDAQ:IMVT – Get Free Report) and Solid Biosciences (NASDAQ:SLDB – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current ratings […]